IP Library Granted Patent US 9,005,637
Granted Patent B2
US 9,005,637 · App. 13/857,813 · Granted Apr 14, 2015

Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,005,637
App. No.
13/857,813
Granted
Apr 14, 2015
Kind
B2
Abstract

Compositions and methods for combination therapy are provided. The compositions comprise a multiple unit dosage form having both a therapeutic agent and a nutritional supplement. The combination therapy is useful for restoring a nutrient depletion associated with a particular disease state. Additionally, the combination therapy can prevent or attenuate the depletion of a nutrient caused, in whole or in part, by the co-administrated therapeutic drug. Methods of manufacturing the formulations are likewise described.

Claims (14)

1. A multiple unit dosage form for oral administration comprising:

an effective amount of a therapeutic agent, a barrier layer, and a chromium layer, wherein the therapeutic agent and the chromium layer are formulated as a single dose, wherein the barrier layer is disposed between the therapeutic agent and the chromium layer, separating the chromium layer from the therapeutic agent to prevent interaction between the therapeutic agent and the chromium layer, wherein the therapeutic agent is located at the center of the dosage form and the chromium layer surrounds the barrier layer.

2. The multiple unit dosage form of claim 1 , wherein the therapeutic agent is selected from the group consisting of analgesics, anesthetics, anxiolytics, antidepressants, antipsychotics, anticonvulsants, nervous system stimulants, antiemetics, hallucinogens, mood stabilizers, bronchodilators, decongestants, anti-proliferatives, angiotensin converting enzyme inhibitors, antiarrhythmics, antianginals, antihypertensives, antihyperlipidemics, anticoagulants, antiplatelets, beta blockers, diuretics, thrombolytics, vasodilators, antacids, antidiarrheals, H2-receptor antagonists, proton pump inhibitors, laxatives, anti-inflammatories, antirheumatics, corticosteroids, muscle relaxants, anti-histamines, antibiotics, anti-virals, protease inhibitors, vaccines, anti-protozoals, anti-fungals, antihelmintics, anti-diabetics, alpha glucosidase inhibitors, DPP-4 inhibitors, chemotherapeutics, steroids, immuno-suppressants, hormonal contraceptions, selective estrogen receptor modulators, fertility agents, anti-pruritic, and combinations thereof and pharmaceutically acceptable salts and solvates thereof.

3. The multiple unit dosage form of claim 1 , wherein the therapeutic agent comprises an anti-diabetic agent.

4. The multiple unit dosage form of claim 1 , wherein the barrier layer comprises a controlled-release coating.

5. The multiple unit dosage form of claim 1 , wherein the barrier layer comprises a delayed-release coating.

6. The multiple unit dosage form of claim 1 , wherein the barrier layer comprises an enteric coating.

7. The multiple unit dosage form of claim 1 , wherein the barrier layer is selected from the group consisting of a sugar, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, hydroxypropyl cellulose, methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, carboxymethylcellulose sodium and combinations thereof and pharmaceutically acceptable salts and solvates thereof.

8. The multiple unit dosage form of claim 1 , wherein the chromium layer comprises one or more chromium complexes selected from the group consisting of a chromium polynicotinate, chromium picolinate, chromium acetate, chromium histidinate, chromium nicotinate, chromium chloride, and chromium yeast.

9. The multiple unit dosage form of claim 1 , wherein the chromium layer comprises one or more chromium complexes present in an amount effective for the prevention treatment of chromium deficiency.

10. The multiple unit dosage form of claim 1 , wherein the chromium layer comprises between about 50 ng and about 2,000 ng of chromium.

11. The multiple unit dosage form of claim 1 , wherein the chromium layer comprises chromium histidinate.

12. The multiple unit dosage form of claim 1 , wherein the chromium layer comprises chromium picolinate.

13. The multiple unit dosage form of claim 1 , wherein the multiple unit dosage form is formulated for administration to a human.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2023
From: JDS THERAPEUTICS, LLC
To: BONAFIDE HEALTH, LLC
Reel/Frame 065072/0787 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2019
From: KOMOROWSKI, JAMES R.
To: NUTRITION 21, INC.
Reel/Frame 048734/0587 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2019
From: NUTRITION 21, INC.
To: N21 ACQUISITION HOLDING, LLC
Reel/Frame 048734/0608 →
CHANGE OF NAME Recorded Mar 28, 2019
From: N21 ACQUISITION HOLDING, LLC
To: JDS THERAPEUTICS, LLC
Reel/Frame 048742/0919 →